Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates

Financial Performance - Sage Therapeutics reported a quarterly loss of $1.56 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.45, and a significant increase from a loss of $0.55 per share a year ago [1] - The company posted revenues of $12.82 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 11.20%, and a decline from year-ago revenues of $77.97 million [2] - Over the last four quarters, the company has not surpassed consensus EPS estimates [2] Stock Performance - Sage Therapeutics shares have increased approximately 33.7% since the beginning of the year, outperforming the S&P 500's gain of 3.1% [3] - The current status of estimate revisions for Sage Therapeutics is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.16 on revenues of $15.55 million, and for the current fiscal year, it is -$3.87 on revenues of $87.12 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Sage Therapeutics operates, is favorable, ranking in the top 26% of over 250 Zacks industries, suggesting potential for better performance compared to lower-ranked industries [8] Industry Comparison - IDEAYA Biosciences, another company in the same industry, is expected to report a quarterly loss of $0.67 per share, reflecting a year-over-year change of -28.9%, with revenues anticipated to be $7 million, up 78.6% from the previous year [9]